Chronic Presence of Epstein Barr Virus in Sulcular and Junctional Epithelial Tissue From Gingiva is Associated With Severe Periodontitis
The recruitment status of this study is unknown because the information has not been verified recently.
Verified November 2010 by Centre Hospitalier Universitaire de Nice.
Recruitment status was Recruiting
Recruitment status was Recruiting
Sponsor:
Centre Hospitalier Universitaire de Nice
Information provided by (Responsible Party):
Centre Hospitalier Universitaire de Nice
ClinicalTrials.gov Identifier:
NCT01246648
First received: November 17, 2010
Last updated: August 6, 2012
Last verified: November 2010
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The etiopathogenesis of periodontal disease results from complex interaction between infectious agents, mainly including bacteria, and host cellular and humoral immune responses. However it is thought that bacteria-induced pathogenesis is not sufficient alone to explain all biological and clinical features of the destructive periodontal disease. The main hypothesis is that herpesviruses, such as Epstein-Barr Virus, may participate as well by altering epithelial gingival cell biology and consequently may promote the initiation and progression of periodontitis.
| Condition | Intervention |
|---|---|
|
Parodontitis Aggressive Parodontitis Chronic |
Procedure: Biopsy Procedure: biopsy |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Basic Science |
Further study details as provided by Centre Hospitalier Universitaire de Nice:
Primary Outcome Measures:
- Presence/absence of EBV in the epithelial cells of periodontal pockets (by Immunofluorescence and in situ Hybridization [ Time Frame: at time = 0 (baseline) ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- Presence/ absence of latency and/or lytic proteins (by immunofluorescence and in situ hybridization [ Time Frame: at time = 0 (baseline) ] [ Designated as safety issue: No ]
- - Epithelial tissue infected (by Immunofluorescence and In situ Hybridization) : detection of oral gingival epithelium, sulcular epithelium, junctional epithelium. [ Time Frame: at time = 0 (baseline) ] [ Designated as safety issue: No ]
| Estimated Enrollment: | 6 |
| Study Start Date: | January 2011 |
| Estimated Study Completion Date: | January 2013 |
| Primary Completion Date: | February 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: chronic periodontitis |
Procedure: Biopsy
dental extraction and gingival epithelial biopsy
|
| Active Comparator: agressive periodontitis |
Procedure: biopsy
dental extraction and gingival epithelial biopsy
|
| Active Comparator: healthy patients |
Procedure: Biopsy
dental extraction and gingival epithelial biopsy
|
Eligibility| Ages Eligible for Study: | 12 Years and older |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | Yes |
Criteria
Inclusion Criteria:
- Men exclusively
- 12 years minimum
- 2 patients affected by chronic periodontitis
- 2 patients affected by aggressive periodontitis
- 2 healthy patients (orthodontics extraction)
- Subject who have read and understood the information note relative under investigation and who have signed the informed consent
- Subject whose legal representative signed the parental consent (if minor patient)
Exclusion Criteria:
- Patient with contre-indication to dental extraction
- Patient witn serious blood disease
- Patient who exhibits systemic condition incompatible with the realization of the study
- Patient treated with oral retinoids, bisphosphonates, oral anticoagulants and anticonvulsivants
- Patient who presents za buccal carcinoma treated with radiotherapy
- Patient who have received during the past 6 months: anti-inflammatory drugs, anti-cancerous or immunosuppressive chemiotherapy
- Patient who presents a linguistic or psychic incapacity to understand information
- Female patient
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01246648
Contacts
| Contact: OLIVERI Vanina, ARC promoteur | 0033 4 92 03 42 54 | oliveri.v@chu-nice.fr |
| Contact: DEL CONT Delphine, ARC promoteur | 0033 4 92 03 47 02 | delcont.d@chu-nice.fr |
Locations
| France | |
| CHU de Nice, Hôpital Saint Roch | Recruiting |
| Nice, France, 06000 | |
| Contact: Severine VINCENT, PH Severine.VINCENT@unice.fr | |
| Contact: Vanina OLIVERI, ARC Promoteur 0033 4 92 03 42 54 oliveri.v@chu-nice.fr | |
| Principal Investigator: Severine VINCENT, PH | |
Sponsors and Collaborators
Centre Hospitalier Universitaire de Nice
Investigators
| Principal Investigator: | VINCENT Severine, PH | CHU de Nice |
More Information
No publications provided
| Responsible Party: | Centre Hospitalier Universitaire de Nice |
| ClinicalTrials.gov Identifier: | NCT01246648 History of Changes |
| Other Study ID Numbers: | 10-PP-13 |
| Study First Received: | November 17, 2010 |
| Last Updated: | August 6, 2012 |
| Health Authority: | France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis) |
Additional relevant MeSH terms:
|
Aggression Periodontitis Behavioral Symptoms |
Periodontal Diseases Mouth Diseases Stomatognathic Diseases |
ClinicalTrials.gov processed this record on June 17, 2013